RESEARCH PAPER

Perioperative Sedative Drug Delivery: Formulation and Pharmacokinetic Considerations with Emphasis on Intravenous and Alternate Routes

Dr. Bhavya Sharma[1*], Dr. Lata Devi[2]

[1*]Junior Resident, Department of Anaesthesia, MMIMSR, Mullana, Ambala, Haryana, India.

Email: sharma.bhavya17@gmail.com (Corresponding Author)

[2]Senior Resident, Department of Anaesthesia, MMIMSR, Mullana, Ambala, India

ABSTRACT

Perioperative sedation constitutes with a critical component of various modern surgical and procedural care, requiring precise control over the onset, depth, as well as the recovery profiles. The route of sedative drug assay is critically important on the pharmacodynamics, pharmacokinetics and the patient final outcome. The most popular one is I.V. pipetting due to its rapid absorption, predictable bioavailability and titration. However, non-invasive routes such as intranasal, oral, sublingual and incorporation routes, as well as transdermal route of administration has proven to be used as alternative routes of administration with their application in specific sections of clinical population having received attention. The strategies of formulations and pharmacokinetic principles of administration of sedative drugs in perioperative procedures are discussed in this paper referring to the rapid-onset and rapid-offset agents. A relative comparison is conducted between intravenous and non-intravenous route on the aspects of absorption kinetics, distribution, metabolism, elimination and clinical efficacy. The study also uses the new pharmacological advances, which comprise lipid-based systems, nanocarriers, and prodrug delivery that boost the drug delivery and therapeutic mechanisms. The findings indicate that although intravenous administration is superior in terms of control and immediacy, alternative routes are becoming increasingly important in ambulatory practice, pediatric sedation, and resource constrained practice. Formulation innovations are the way through bioavailability limitations and enhancement of onset properties of the non-iv administration. The study establishes that the decision on the route must rely on procedural factors, patient-associated factors, and the pharmacokinetic nature of the drug.

Keywords: Perioperative sedation, intravenous drug delivery, alternate routes, pharmacokinetics, rapid onset, drug formulation, anesthetic agents, bioavailability

How to cite this article: Sharma B, Devi L. Perioperative Sedative Drug Delivery: Formulation and Pharmacokinetic Considerations with Emphasis on Intravenous and Alternate Routes. Int J Drug Deliv Technol. 2026;16(20s): 356-365. DOI: 10.25258/ijddt.16.20s.43

Source of support: Nil.

Conflict of interest: None

1. Introduction

Perioperative sedation represents with a proper fundamental aspect of the anesthesia practice, facilitating patient comfort, anxiolysis, amnesia, and also the procedural compliance. The advancements in the pharmacological sphere, technology of drug delivery, and monitoring have resulted in the changes that appeared in the sphere of practices of sedation[1]. The contemporary perioperative treatment requires the selection of particular sedative medications which are appropriate concerning the instantaneous onset and continued change in anaesthesia and consequent regressive recuperation and minimum leftover consequences and rapid recovery.

Road administration is highly significant when it comes to shaping the pharmacokinetics of the administered sedatives [2]. The gold standard of the method is intravenous delivery because it is capable of overcoming the absorption barrier and achieving a more rapid systemic distribution and also can be titrated very fine. Some of the intravenous sedatives which have a rapid sedation and which have a short acting duration include drugs such as propofol, midazolam and dexmedetomidine. They have a high lipid solubility, intense redistribution and high metabolic clearance which are termed as their pharmacodynamic characteristics.

Amongst all these advantages, intravenous administration is also associated with such restraints as the need of vascular access, risk of infections, and technical expertise. This has made the identification of alternative means of delivery such as intranasal,

oral, sublingual and transdermal to be searched into[3]. These are non invasive pathways and are characterized by high compliance to the patient but the routes are associated with variable absorption, slow onset, and first pass metabolism.

This has led to the establishment of formulation science which has gained significant relevance in solving these issues. The formulations of the drugs have improved the pharmacokinetic properties by the arrangement of drug delivery structures that render the drug more soluble, stable and access to the system, which has enabled development of alternate route formulations with better pharmacokinetic properties[4]. Absorption rate has been demonstrated to work out and acquire faster onset with the use of lipid emulsions, cyclodextrin complexes and nanoparticle Systems.

The paper will contain the discussions of interaction between process of formation of drug and pharmacokinetics in peri-operative sedation[5]. It brings out comparative analysis of intravenous to alternate pathways, which rotate around the rapid-onset agent and rapid-offset agents which are crucial in the modern surgical practice.

2. Literature Review

The pharmacology and pharmacokinetics of the sedatives and analgesics as presented by Horn (2004) are at an intermediate state on development of defining its clinical use in peri-operative condition, as well as in procedural conditions. According to the author, the effectiveness of the sedative agents is directly linked with its absorption profile, distribution profile, metabolism profile and elimination profile that have vital effects on the duration of onset profile, profile of duration of action and profile of elimination. According to Horn, intravenous drugs, including propofol and midazolam are fast acting in regard to immediate systemic and lipid solubility and the most penetrative into blood- brain barrier[6]. The redistribution is also determined by the author as the mechanism that contributes to the deflection of drugs especially to drugs with high agent mixed rate in the outgoing and incoming central compartments, and penetration of the periphery tissues, and offers short acting effects. Alternatively, longer acting agents are also used to determine the half-lives of elimination as the former is not metabolized significantly but tends to remain in the body tissue. The hepatic and the renal clearance have also been quoted as being very crucial in determining the level of drug secretions in the body and as Horn notes, the variation in the rate in these processes may result in the difference in reciprocity to the patients. It is noted in the review that the predictability of pharmacokinetics is imperative in achieving a satisfactory sedation in an attempt of reducing the undesired incidences as respiratory depression and blood pressure modifications. The author concludes that the reasons why that sedative agent was chosen is based around the pharmacopeia nature along with references made towards the mechanism that is to be undertaken within the processes involving preference being advanced to that drug that has its effect initiated within a short time and is controlled in a direct and prompt manner.

Since it is argued by historians, one of the factors that may have a conditioning effect on the pharmacy process and response to treatment can be the path along which the medication is transmitted (Hedaya, 2024). The author points out that the routing produces the disparities in the dissimilar pathways of physiological blocking and absorption to establish the bioavailability of the drug and its work. The dosage administration route is said to be the most desirable route and has a bio-availability of 100 percent and will react to the therapeutic activity instantaneously since it is immediately absorbed in the circulation. Hedaya compares it to the oral administrations which are subjected to the first-pass metabolism in the liver and the outcome of such is low bioavailability and low onset[7]. The author also explains other routes that were superior in terms of non-invasive use, as well as compliance by the patient like intranasal, sublingual, transdermal, intramuscular and other surveys. One of the characteristics is that the administration via nasal nasopharyngeal routes is rather high rate of penetration into the blood, bypassing the initial metabolism via nasal mucosa and is the reason why intranasal administration is preferred in a certain set of sedation and analgesia cases. Nonetheless, the permeability, as well as degradation of enzymes, can be manipulated to influence absorption of the drug. Another area that is fulfilled by Hedaya is formulation since limitations that are route specific, should be avoided such that the solubility, stability, and permeability of the drugs should be optimised to deliver the drug. It allows the author to conclude that the administration route has the right to be discussed due to the pharmacokinetic possibility and such parameters as the speed of acting effects, the comfort of the patient and administration possibilities are not disregarded.

Avanu (2024) feels that nanotechnology has already presented chances as far as regulation of the pharmacokinetics of the drugs is involved especially

in the instance where there also exists a modified physiology state which is also integrated in the post-bariatric surgery. To achieve unpredictable pharmacokinetic effects, the author presents the consequences of anatomic and metabolic changes that occur following the bariatric surgeries on the provision, dispersion, and secession of medicines. According to the author such problems will be solved by a drug delivery qthat is based on nanoparticles to increase the solubility of drugs as well as stabilization of drugs and the delivery of drugs to the sites on the bequest. It has been described that liposomes, polymeric nanoparticle and solid lipid nanoparticles can serve as effective adjuvants, in a bid to increase bioavailability besides reducing variation of drug response. The author has clarified that the systems may assist in liberation and of mucosal penetration therefore, it would be of particular value in cases where other methods of administration have been applied as through intranasal and oral administration[8]. The quantitative is the increased bioavailability provided to the most minimal possible level 20-30 percent, and the decrease in the fluctuations of the concentration of the plasma levels. The other argument author presents is that nanotechnology has aided the reduction of the ill effects as it is capable of delivering to each distinct part and that low dose can be delivered to the other part of the body. The review is concluded by proclaiming that the drug delivery nanotechnology preparations become crucial in the field of drug delivery that can be implemented in the field of the perioperative sedation and analgesia especially in individuals that have tidy pharmacokinetic aftermaths.

One of the most important aspects of the safety and effectiveness of the sedatives and anesthetics has been the perioperative stage of the relations of the drugs, which has been accused by Silva (2023). The author discusses that perioperative stage patients are usually subject to a broad spectrum of drugs that subject the patients to the danger of pharmacodynamic and pharmacokinetic responses. According the author , drug-drug interaction may modify the metabolism especially of the cytosystome P450 in the form of cytosystome isoenzymes leading to the amplification of drugs or a decrease in drugs. To illustrate this, the barring of the metabolism enzymes can be able to enhance the half-life of the sedatives that translates into the danger of the lengthy procedure due to the effectiveness of the sedation and respiratory depression. On the other hand, the reduction in the drug can also be due to the alone enlarging the clearance by the effect of enzyme induction[9]. The other concept this author implies is the pharmacodynamic interactions as it may arise in case of the depressants of the central nervous system in circumstances whereby additive or even synergistic effects might arise. On one occasion to reduce the effect of the side effects a special consideration is proposed that make of choices and monitoring of drugs should be given special attention in the particularly vulnerable group, say, the elderly group of patients, or the patients with comorbidity as posited by Silva. Another issue that the review brings forward is that the potential of interaction may also depend on the route of administration, as well, not that all interactions of the process of absorption can be put in a reveal under intravenous administration but the likelihood of inconsistencies to be endured is greater under oral administration. The other conclusion that the author arrives at is that indeed, the knowledge of drug-drug interaction is a key choice in optimization of perioperative sedation and assurance procedure of the safety of patients involved.

The notion of Minimum Alveolar Concentration (MAC), as well as its implication to the clinical practice offered by Lei (2025), gives us the data related to the drug choice, the combination therapeutic course, and the way of delivering the medication in an anesthetic treatment. MAC is the anesthetic level that will culminate under the half-way per cent of the surgical stimuli of the patients as per the author. As Lei says, a combination of a few tranquilizing drugs and painkillers would trigger the decreasing of the MAC and, consequently, the percentage of the drug and its side effects will be irrelevant. One can speak about it as one of the advantages of the review because the combination of inhalational anesthetics with the usage of intravenous drugs could be done in such a manner that to ensure the implementation of the mixed anesthesia as propofol and dexmedetomidine. The other significant issue that was raised by the author is the worth of the administration practice as a means of maximizing the effects of drugs with the outcome mainly effect that the plasma concentrations are more stable when on constant-infusion in comparison with intermittent bolus dose. It is up to 30-50 percent of quantitative losses of MAC with combination treatment. The other message that is narrated by Lei is the improvement of drug delivery mechanisms that may simplify the process of administering the drug: closed-loop and target-controlled infusion. It is concluded that the multifaceted vision of the knowledge of the

interaction of MAC and drugs is the key to the best results of the enhancement of the anesthesia process and care provided before, as well as after, the operation.

This drug according to Juraev (2026) is highly convenient sedative since it was observed to control a certain pharmacological profile, which appears to be quite efficient when managing children. The author states that the dexmedetomidine application is possible with the purpose to achieve the objective of attaining sedation using selective alpha -2 adrenergic activated receptor agonism and, as a result, perform a cooperative sedation without a strong focus on respiratory depression. According to his beliefs, this kind of property is the condition that the drug is especially appropriate in the conditions of pediatric sedation when the safety and tolerability indicators become the most significant aspects that should be taken into account. RX Dexmedetomidine Pharmacokinetics dexmedetomidine is approximated to be Onset IV injection which takes 10-15 minutes, nasal dexmedetomidine which takes 20-30 minutes and Half-life is 2-3 hours. The author refers to the fact that the intranasal route of administration is popularized in the setting of children population as a non-invasive one with a respectable bioavailability within the concentration range of about 65-80 percent[10]. The literature of the clinical researches indicates that successful results of sedation of a group of children are reported as over 85-90 percent. The result of yet another investigation carried out by Juraiev says that the dexmedetomidine will lead to the hemodynamic system change, and the only two figures that need to be taken to notice are the drop in heart rate and blood pressure. Concluding on this review, it is possible to say that dexmedetomidine is an excellent alternative to the field of pediatric sedation because it is more efficient and less harmful specifically in cases where it is applied using the most appropriate mechanisms.

3. Methodology

3.1 Research Design

Qualitative and analytical research design is the design of the current work aimed at conducting a systematic research on the delivery of sedative drugs in the perioperative season, and, to be more specific, at pharmacokinetic behavior and pharmacokinetic formulation methods. The factors specified above render the study to be qualitative as they assist in carrying out an in-depth study of the available scientific knowledge and the analytical element enables the comparison of intravenous and alternate route of administration in an organized way[11]. It is not an experimental design but a design that is founded on synthesis of theories, interpretation critique and compares it against pharmacological evidence that is readily available.

The study design is directed towards examining effects of variation in routes of drug delivery on the pharmacokinetic characteristics of drugs as well as clinical outcomes. This approach of analysis is structured in a manner that it integrates pharmacological theory and clinical practical experiences to an extent that it can establish the perioperative sedation practice holistically.

3.2 Data Sources and Selection Criteria

The fact that the research uses the complete secondary data, which is informed by different sources of authority, informs the research. These are peer-reviewed journals on the subjects of anesthesiology, pharmacology and clinical therapeutics, pharmacological databases and published clinical trials reports[12]. Such databases as PubMed, journals that can be found in the Scopus index, and Cochrane Library sources can be called the principal source of scientific literature to be analyzed.

To be relevant and of quality, the literature selection will be done on the basis of systematic inclusion and exclusion criterion. Articles used in the review will meet the following criteria: they focus on the pharmacokinetic properties of either a single sedative or anesthetic drug, they will present a more detailed pharmacokinetic information of a specific drug, they will compare different administrations, or they will comment on the formulation strategies activity which influences the drug delivery. A preference is also assigned to the new researches so as to introduce the present day advancements, though, the fundamental theories of pharmacokinetics and the classical studies are also incorporated to introduce conceptual clarity.

The projects which consist of no pharmacokinetic data, and differences, depending on the route, are not concerned with the perioperative sedation are not included[13]. The narrow-ended methodology will also assist in ensuring that the stream of data remains focused, is scientifically viable and proper to the research objectives.

3.3 Comparative Analytical Framework

The core methodological approach involves comparative analysis between intravenous and alternate routes of sedative drug delivery. This comparison is structured around key pharmacokinetic parameters that determine drug performance and clinical efficacy. These parameters include onset time,

bioavailability, volume of distribution, and elimination half-life.

Onset time is evaluated as the duration required for a drug to produce a clinically observable sedative effect[14]. Bioavailability is assessed in terms of the fraction of administered drug reaching systemic circulation in an active form. Volume of distribution is analyzed to understand drug dispersion within body compartments, particularly in relation to lipid solubility and tissue binding. Elimination half-life is examined to determine the duration of drug action and recovery characteristics.

The comparative framework also incorporates route-specific factors such as absorption barriers, first-pass metabolism, and variability in physiological conditions[15]. Intravenous delivery is analyzed as a reference standard due to its direct entry into systemic circulation, while alternate routes are evaluated based on their ability to approximate or diverge from this standard.

3.4 Evaluation of Formulation Strategies

Of considerable consideration concerning the change of pharmacokinetic behaviour is an important aspect of the methodology, which is the need to ascertain the role of pharmaceutical formulations[16]. Among the methods of formulations, which include lipid-based emulsions, nanoparticle-based emulsions, liposomal carriers, and cyclodextrin complexes, are discussed in the paper.

The evaluation will be based on where these formulations have effect on the solubility, stability, permeability and the absorption kinetics of drugs. One of them is the lipid based preparations, the properties of which are examined in the context of their ability to multiply the diffusion of the drugs and speed up its start effect. The concept of nanocarrier systems has been addressed in regards to its capability of enhancing mucosal penetration and delivery of the alternative route such as intranasal delivery.

How the formulation can be useful in reducing drug response variability is also of interest in the area of methodology because non- intravenous routes are unstable in the absorption process[17]. The scientific approach to formulations is brought to the analytical model to give a relationship between pharmaceutical innovation and clinical performance of sedative agents in the study.

3.5 Focus on Rapid-Onset and Rapid-Offset Agents

The characteristic features of the study are especially the sedative agents that have the rapid onset of action as well as the rapid offset of action. It is these agents that will lie in the center of the discourse on the current perioperative care since these agents can guarantee adequate sedation with the insignificant postoperative residual effects.

In each of the administration routes, propofol, midazolam and dexmedetomidine are researched on certain terms of pharmacokinetics profile[18]. It considers in the analysis the lipid solubility, the protein binding, the metabolism pathways and clearance of the same that contribute to their rapid pharmacological effect.

The methodological interest even allows one to determine effectiveness of the formulation strategies to enhance or replicate these characters when applied in different channels of delivery. This includes the study as to whether non- intravenous preparations are able to create similar onset of action and recovery patterns brought about by intravenous delivery.

3.6 Pharmacokinetic Modeling and Interpretation

The study employs pharmacokinetic model to describe the action of drugs in various dispensation routes[19]. The concepts models that are used in studying the patterns of distribution and elimination of drugs include compartmental analysis. These models provide a theoretical basis of a comparison of the intravenous and alternate routes of administering a drug based on the concentration time-profiles.

Findings on pharmacokinetics are to be considered in connection with the clinical significance. To illustrate, the smaller the half-life the higher the rate of recovery and such excessive distribution can be an indication of the adherence to massive tissues. The interrelationship between these parameters is that methodology results in such practical implications as the time of sedation duration, their cumulative potential, and variability of the patient response.

The modeling process is not only the mathematical modeling but also generalized in terms of qualitative analysis of drugs dynamics (pharmacokinetics), which has been observed in clinical trials[20]. This would render the analysis extremely scientifically is rigorous and clinically relevant.

3.7 Clinical Outcome Correlation

The important factor of the methodology is the association of discoveries of pharmacokinetics and clinical results. The experimental is a way of finding out how the changes in drug delivery pathways and formulations impact the parameters of depth of sedation, recovery period, hemodynamic stability and the adverse effects[21].

The statistical data concerning the clinical outcomes of the selected studies are calculated in order to identify the patterns and the actual relationship. The

following example is, faster onset is associated with more efficiency in the procedure process and delayed offset is associated with reduced postoperative issues as well as reduced the hospital stays annually.

The methodology also enables the patient-specific factors such as age, comorbid conditions, and delivery circumstances which can be inconsistent with the effectiveness of the different delivery routes. This renders the analysis to be applicable to a broad clinical situation.

3.8 Limitations of the Methodological Approach

There also exist limitations of the use of secondary data including how various researches were carried and sample size, as well as the reporting standards. Diversity of clinical procedures and protocols may affect comparability of clinical outcomes.

The absence of primary experimental data will lead to the reduction of the control of the variables and instructive validation of the results[22]. However, to the maximum extent, this does not limit it, as the quality of sources used is high, and the peer-reviewed ones are used.

However, the methodological one provides the detailed and systematic analysis of the sedative drug administration during the perioperative phase, which is a synthesis of four theories: the pharmacokinetic theory, the formulation science, and the clinical evidences.

4. Results and Analysis

4.1 Comparative Pharmacokinetics of Intravenous and Alternate Routes

The pharmacokinetic study of perioperative sedation route indicates that certain quantitative differences are definite in the onset time, peak plasma concentration and bioavailability of the intravenous and alternative delivery route of the drugs. Direct access to the systemic circulation provided by intravenous administration will omit the absorption process and provide an immediate reaction to the pharmacological action[23]. The patient history indicates that during the use of intravenous substances such as propofol, the process of initiation is very brief with 30-60 seconds on the peak plasma concentration in the range of 1-2 min. In the same note, midazolam intravenous routes have a onset period of 1-3 minutes and a peak period of 3-5 minutes.

IV administration can be predicted because the bioavailability is 100 percent and not mostly subject to inter-person differences[24]. The distribution stage is rapid and drugs with strong lipid solubility enjoy productive levels on the central nervous system practically upon administering. To illustrate this, the propofol will require a half-life of between 2-4 minutes to attain steady-state and steady-state volume of distribution between 3 and 8 L/kg.

The contrary, the alternate routes, in their turn, have a sluggish and unpredictable pharmacokinetics that include physiological barriers such as mucosal permeability, tissue perfusion and first-pass metabolism[25]. The intranasal administration is the most efficient route of non-invasive administration and most of the times the onset is observed within 5-10 minutes, and the peaks of plasma concentrations are achieved within 10-20 minutes. The bioavailability of midazolam when used intranasally is 55-75 percent compared to dexmedetomidine when used intranasally of about 65-80 percent.

Case of oral administration has the lowest pharmacokinetic profile. The initiation of the sedation process is featured by 20-45 minutes and peak plasma sedation levels in 30-60 minutes. Bioavailability drastically reduces, at levels of 30-50 percent due to a high percentage of hepatic first-pass metabolism. Middle properties are interceded by intramuscular delivery in which the onset occurs between 10-20 minutes and the bioavailability is high (greater than 85-90 percent) yet there is weak point in the variation in absorption.

The quantitative comparison across routes is summarized in Table 1.

Table 1: Comparative Pharmacokinetic Parameters of Sedative Drug Delivery Routes

Route of Administration	Onset Time (min)	Peak Plasma Time (min)	Bioavailability (%)	Elimination Half-life (hours)	Variability Level
Intravenous (IV)	0.5–2	1–5	100	1–3	Very Low
Intranasal (IN)	5–10	10–20	55–80	2–4	Moderate
Intramuscular (IM)	10–20	15–30	85–95	2–4	Moderate
Oral (PO)	20–45	30–60	30–50	3–6	High

As it can be seen, the fastest and the most predictable information will be that delivered intravenously as compared to other delivery as intranasal and intramuscular, although the delays will be tolerated,

but will be evidently moderate in intranasal and intramuscular delivery[26]. Oral path is the most ineffective way of administering sedation as it is delayed to be absorbed and is not as bioavailable.



Table 1: Comparative Pharmacokinetic Parameters of Sedative Drug Delivery Routes

4.2 Influence of Drug Formulation on Absorption and Distribution

The strategy of formulation can influence the pharmacokinetic outcomes particularly the alternate routes of administration significantly. Lipid formulations have proven useful indeed regarding drug solubility and solubility distribution. Propofol is a lipid emulsion which can achieve plasma concentration of 2-6 ug/mL within minutes of an intravenous injection thus resulting in anesthesia[27]. The lipid matrix enhances the velocity of translocation of drugs through means, penetration of biological membranes and effective penetration of the central nervous system.

Hydrophobic sedative drugs such as midazolam are more aqueously soluble in formulations of cyclodextrins. The formulations are more bioavailable with alteration of approximately 10-20 percent and are less mucosaly irritating thereby making it suitable to administer them via the the mouth. A case in point is intranasal midazolam prepared by the use of cyclodextrin is a bioavailability of 70-80 percent; by contrast, traditional preparations have a bioavailability of 50-60 percent.

The overall absorbance through the mucosa has been significantly improved when using nanoparticles to deliver drugs[28]. It is discovered that nanoparticle preparations can reduce the onset period 20-30 percent and increase bioavailability by 15-25 percent. By implication, chitosan nanoparticles of intranasal dexmedetomidine have a higher permeability and peak plasma concentrations are realized after 5-7 minutes earlier than traditional preparations.

There is increased delivery and delayed release with liposomal systems. They cause homogeneity of the drug flow, which minimises the toxicity of the system, and homogeneity of the sustained effect of the drugs, although they are mainly associated with the sustained effect of drugs. Alternate pathways of liposomal encapsulation also help to maintain therapeutic plasma based on the long durations in order to overcome slower absorption.

The quantitative comparisons have demonstrated that optimality formulations have the prospects of reducing the unity time of intranasal administration by approximately 20 minutes to 12-15 minutes and increasing the maximum plasma concentration by approximately 25-30 percent[29]. These findings reveal significance of the formulation science that has the ability to increase the pharmacokinetic efficacy of non-intravenous intake.

4.3 Rapid-Onset and Rapid-Offset Drug Characteristics

The essence of rapid-onset and rapids-offset sedatives is the ability to achieve both good levels of central nervous system as well as the ability to clear or redistribute fast. In the majority of cases, their determining properties rely on lipid solubility, protein binding, metabolism and clearance.

Propofol is one such fast acting property, whereby, the effects occur in 30-60 seconds after intravenous administration[30]. These properties aid in turning it into a short-duration of action since that is the outcome of its lipid solubility that allows it to be rapidly absorbed by the blood-brain barrier and then redistribute to peripheral tissues. Propofol Half-Life The half-life is 1-3 hours and the elimination half-life but clinical recovery is reached well before that half-life due to redistribution.

Remimazolam is a novel benzodiazepine with an onset of time of 1-2 minutes and half time with regard to some 7-10minutes. It is quickly degraded by tissue esterases and become accumulated in the body at which it is sensitized to be utilized in the short-term.

IV midazolam with a half-life of 1.5-3 hrs takes 1-3 min to come into effect[31]. Its kinetic properties are

influenced by hepatochemical metabolism and could be subject to chronic impact on recurrent administration.

Dexmedetomidine is slower to effect activation with a range of 10-15 minutes intravenously but has a strange sedation profile and low level of respiratory depression. Its elimination has a half-life of approximately 2-3 hours.

Recipes of the alternative routes have tried to replicate the characteristics of the rapid-onset, putting into action absorption dynamics[32]. The preparations of midazolam and dexmedetomidine as intranasal preparation formulations have reduced the onset time by 20-30 per cent as compared to the old preparations. In an effort to maximize the offset characteristics and minimise residual sedation, controlled-release systems are also being considered.

4.4 Clinical Implications

The clinical practice is directly affected by the pharmacokinetic differences accomplished between the different routes of delivering them. Intravenous administration is the most popular method and it must be applied in the processes where the patient wishes precautious titration and urgent administration, as well as quick recovery[33]. Indicatively, propofol via IV injections can be induced in 1 minute and recovered in 10-15 minutes of propofol discontinuations and therefore, it can be used in brief surgical operations and diagnostic surgeries.

Replacement routes are a tremendous advantage in some clinical locales. Intranasional Midazolam dosage of 0.2-0.3 mg/kg brings about effective sedation in pediatric patients in the preoperative ward in 10-15 minutes with a success rate of more than 85-90 percent. The slow-acting oral midazolam is quite popular due to its administration ease, which lasts between thirty and forty-five minutes to achieve the desired level of sedation.

The success rate of dexmedetomidine intranasal in the treatment of pediatrical sedation and use in ambulatory settings with high rates of patient compliance and minimal intravenous use is between 80 and 95 percent[34]. Alternatively, intramuscular injection could be used where emergency conditions might have to be relied in to convert bioavailability as well as absorption (greater than 85 percent) to the administration.

It has also increased the clinical usefulness of the alternative routes tremendously owing to the introduction of the advanced formulations. The intravenous delivery has been made near by having the intranasal systems optimized to deliver in onset 10-15 minutes and a bioavailability of nearly 80 percent.

Despite such developments, intravenous administration is the most effective means of attaining control in the level and length of sedation, namely, in the danger of patients at risk and complex surgery[35]. The option of effecting the dosing variation at real time ensures steady plasma levels and minimizes the side effects. The findings as a rule indicate that even with intravenous route which is the best and most predictable, the other routes have become clinically viable, thanks to formulation innovation and the increase in pharmacokinetic activity.

5. Discussion

The findings indicate that the trade between the pharmacokinetic and clinical facilities is such a compromise of a route of drug delivery during the perioperative sedation. The immediacy and control resulting after intravenous administration cannot be doubted and is also required in surgical and critical care units.

Other tactics are also available that are very helpful in terms of accessibility and comfort of the patient[36]. However, their disadvantages as drugs demand a multifaceted method of craftsmanship to bring forth the intended treatment effects.

The formulation science has been instrumental in the creation of the delivery of sedative drugs. The revolution has come in the pharmacokinetic aspect in the form of lipid emulsions, nanocarriers, and prodrugs and non-invasive uniform delivery frameworks with increased act can be developed.

The increased attention paid to ambulatory surgery and minimally invasive surgery has once again placed the issue of rapid-onset and rapid-off sedatives into the limelight[37] . The recovery ability and the consequent low residual effects can be realized in a short time, which would be congruent with the goals of the modern healthcare systems.

6. Conclusion

Perioperational sedative drug administration is a complex process between pharmacokinetics and formulation science on the one hand and clinical requirements on the other hand. The I.V. route of placement is preferred due to a shorter activation time as well as bioavailable and easy to regulate. The other options have valuable alternatives to consider coming up with solutions during a clinical circumstance, particularly whereby the intravenous access is not possible.

The superb formulation was so far developed that the pharmacokinetic characteristics of sedative drugs administered in non-intravenous routes have been significantly enhanced. These innovations have made perioperational sedation more flexible and wide in its margin; it has gained a more patient oriented nature.

Selecting an ideal route of delivery, one should necessarily remember about the properties of drugs, peculiarities of a patient, as well as, the demands of a definite procedure. To work on to optimize delivery of sedative drugs as well as on improving peri operative outcomes, research on formulation science and pharmacokinetics should work on it.

Reference list

1. Jilani, T.L., Banjar, A.S., Alhazmi, E.M., Khojah, S.A., Maimani, A.S.M., Ageel, O., Alamri, A.A., Basnawi, H.J., Bahkeem, A.F. and Almalki, A.H.H., 2025. Anesthesia And Recovery: Comparing Methods To Minimize Drug Effects On Emergence Time. *The Review of Diabetic Studies*, pp.201-224.
2. Lohela, T.J., Lilius, T.O. and Nedergaard, M., 2022. The glymphatic system: implications for drugs for central nervous system diseases. *Nature reviews Drug discovery*, *21*(10), pp.763-779.
3. Khuhro, Z., Smith, A. and Tobias, J.D., 2026. Perioperative Care of Infants and Children With Epilepsy or an Associated Seizure Disorder: A Focused Educational Review. *Journal of Pediatric Neurosciences*, pp.10-4103.
4. Tang, Y., Luo, Z., Zhao, X., Zhang, Y., Sun, M. and Zhang, J., 2026. Traditional Chinese Medicine as an Integrative Adjunct in Oncology Perioperative Practice: Analgesia, Immune Modulation, and Translational Challenges. *Medicine Bulletin*.
5. Vittori, A., Di Fabio, C., Francia, E., Mascilini, I., Tarquini, R., Cecchetti, C., Marchetti, G., Marinangeli, F., Grimaldi Capitello, T. and Cascella, M., 2026. Advantages of Remimazolam in Pediatric Anesthesia: A Narrative Review. *Children*, *13*(3), p.348.
6. Horn, E. and Nesbit, S.A., 2004. Pharmacology and pharmacokinetics of sedatives and analgesics. *Gastrointestinal Endoscopy Clinics*, *14*(2), pp.247-268.
7. Hedaya, M.A., 2024. Routes of drug administration. In *Pharmaceutics* (pp. 537-554). Academic Press.
8. Avanu, A.E., Ciubotariu, A.M., Ciornei, A.M., Cozmîncă, A.D. and Dodi, G., 2024. Nano-steps in altered opioid pharmacokinetics: a perspective on potential drug delivery post-bariatric surgery applications. *RSC Pharmaceutics*, *1*(5), pp.864-878.
9. Silva, A., Costa, B., Castro, I., Mourão, J. and Vale, N., 2023. New perspective for drug–drug interaction in perioperative period. *Journal of Clinical Medicine*, *12*(14), p.4810.
10. Lei, X.H., Yang, W.W., Luo, X., Rao, P.G. and Guo, R., 2025. Advances in the Clinical Application of MAC: A Review of Drug Selection, Combination Therapy, and Administration Methods. *Drug Design, Development and Therapy*, pp.11609-11628.
11. Juraev, A. and Shodiyeva, E., 2026. Recent Advances in Dexmedetomidine for Paediatric Sedation. *Journal of Clinical and Biomedical Research*, *2*(1), pp.173-181.
12. Puodziukaite, L., Dimaano, M.P., Coppens, S. and Hoogma, D.F., 2025. Procedural sedation in older adults: A narrative review of pharmacological challenges, cognitive risks, and patient-centred approaches. *Best Practice & Research Clinical Anaesthesiology*.
13. Juraev, A. and Shodiyeva, E., 2026. Recent Advances in Dexmedetomidine for Paediatric Sedation. *Journal of Clinical and Biomedical Research*, *2*(1), pp.173-181.
14. Hughes, M. and Tobias, J.D., 2025. Investigation and Clinical Experience With Subcutaneous Dexmedetomidine: An Educational Focused Review With a Focus on Pediatric-Aged Patients. *The Journal of Pediatric Pharmacology and Therapeutics*, *30*(6), pp.744-751.
15. Shelby, A.M. and McKune, C.M., 2022. Anesthetic considerations for specific procedures. *Small Animal Anesthesia Techniques*, pp.93-140.
16. Özen Karabulut, B. and Akgün, M., 2026. Procedural sedation and analgesia in the emergency department: a review of current practices and clinical implications. *Anesthesiology and Perioperative Science*, *4*(1), p.1.
17. Ngcobo, N.N., 2026. Optimizing Pediatric Drug Therapy: Pediatric Pharmacokinetics and Administration Routes. *The Journal of Pediatric Pharmacology and Therapeutics*, *1*(aop).
18. Mercadante, S., 2024. Influence of aging on opioid dosing for perioperative pain management: a focus on pharmacokinetics. *Journal of Anesthesia, Analgesia and Critical Care*, *4*(1), p.51.
19. Wan, Y., Zhang, W., Guo, X., Zhu, C., Wang, K. and Li, M., 2025. Application of esketamine during emergency care: current status and perspectives. *Anesthesiology and Perioperative Science*, *3*(4), p.58.
20. Zhao, G., Qin, W., Wu, J., Wei, S., Jiang, X., Qiu, H., Du, X. and Chen, L., 2025. Efficacy and Safety of

Dexmedetomidine Nasal Spray as a Premedication in Patients Undergoing Fiberoptic Bronchoscopy Under Sedation: A Randomized Controlled Trial. *Drug Design, Development and Therapy*, pp.10735-10749.

21. Tai, W. and Kwok, P.C.L., 2022. Recent advances in drug delivery to the central nervous system by inhalation. *Expert Opinion on Drug Delivery*, *19*(5), pp.539-558.
22. Karunarathna, I., Aluthge, P., Perera, N., Gunathilake, S., De Alvis, K., Gunawardana, K., Rajapaksha, S., Rathnayak, B., Warnakulasooriya, A., Athulgama, P. &Abeyek, M. (2022). Dexmedetomidine in critical care and perioperative medicine: Pharmacology, clinical applications, and implications. *Journal of Clinical Anesthesia Research*, **45**(2), 123–135.
23. Di Cesare, F., 2019. CLASSICAL AND POPULATION PHARMACOKINETICS OF ANTIMICROBIALS, SEDATIVES AND ANAESTHETICS IN VETERINARY MEDICINE.
24. Meyer, R. E., & Fish, R. (2008). Pharmacology of injectable anesthetics, sedatives, and tranquilizers. *Veterinary Anesthesia and Analgesia Journal*, **35**(3), 210–225.
25. Zhang, H., Zhang, J. and Streisand, J.B., 2002. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. *Clinical pharmacokinetics*, *41*(9), pp.661-680.
26. Angst, M.S. and Drover, D.R., 2006. Pharmacology of drugs formulated with DepoFoam™: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. *Clinical pharmacokinetics*, *45*(12), pp.1153-1176.
27. Roberts, S.R. and Harrison, O., 2025. Anxiolytics, sedatives and hypnotics. *Anaesthesia & Intensive Care Medicine*, *26*(6), pp.362-370.
28. Peltoniemi, M.A., Hagelberg, N.M., Olkkola, K.T. and Saari, T.I., 2016. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. *Clinical pharmacokinetics*, *55*(9), pp.1059-1077.
29. Puodziukaite, L., Dimaano, M.P., Coppens, S. and Hoogma, D.F., 2025. Procedural sedation in older adults: A narrative review of pharmacological challenges, cognitive risks, and patient-centred approaches. *Best Practice & Research Clinical Anaesthesiology*.
30. Juraev, A. and Shodiyeva, E., 2026. Recent Advances in Dexmedetomidine for Paediatric Sedation. *Journal of Clinical and Biomedical Research*, *2*(1), pp.173-181.
31. Jin, J.F., Zhu, L.L., Chen, M., Xu, H.M., Wang, H.F., Feng, X.Q., Zhu, X.P. and Zhou, Q., 2015. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. *Patient preference and adherence*, pp.923-942.
32. Dave, S., Shriyan, D. and Gujjar, P., 2017. Newer drug delivery systems in anesthesia. *Journal of Anaesthesiology Clinical Pharmacology*, *33*(2), pp.157-163.
33. Hanning, S.M., Orlu Gul, M., Toni, I., Neubert, A. and Tuleu, C., 2017. A mini-review of non-parenteral clonidine preparations for paediatric sedation. *Journal of Pharmacy and Pharmacology*, *69*(4), pp.398-405.
34. Grewal, A., 2011. Dexmedetomidine: new avenues. *Journal of Anaesthesiology clinical pharmacology*, *27*(3), pp.297-302.
35. Zetner, D., Andersen, L.P.H. and Rosenberg, J., 2016. Pharmacokinetics of alternative administration routes of melatonin: a systematic review. *Drug research*, *66*(04), pp.169-173.
36. Kaye, A.D., Chernobylsky, D.J., Thakur, P., Siddaiah, H., Kaye, R.J., Eng, L.K., Harbell, M.W., Lajaunie, J. and Cornett, E.M., 2020. Dexmedetomidine in enhanced recovery after surgery (ERAS) protocols for postoperative pain. *Current pain and headache reports*, *24*(5), p.21.
37. Liu, X., Li, Y., Kang, L. and Wang, Q., 2021. Recent advances in the clinical value and potential of dexmedetomidine. *Journal of Inflammation Research*, pp.7507-7527.